AIA
BMRN icon

Arcadia Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arcadia Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4
Closed -$334 – 127
2021
Q2 		$334 Buy
+4
New +$317 ﹤0.01% 235

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Arcadia Investment Advisors's BMRN Position: Q3 2021 in Review

Arcadia Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 4 shares — an estimated $334 sold.

Arcadia Investment Advisors first reported a position in BMRN in Q2 2021 and held it in 1 quarter. The position peaked at $334 in Q2 2021. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Arcadia Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Arcadia Investment Advisors sold 4 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $334.
  • Arcadia Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Arcadia Investment Advisors's BioMarin Pharmaceuticals position peaked at $334 in Q2 2021.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Arcadia Investment Advisors's 13F filing for Q3 2021, filed 19 Dec 2024.